144 related articles for article (PubMed ID: 3164428)
21. Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas.
Shahangian S; Fritsche HA; Hughes JI; Gelder FB
Clin Chem; 1989 Mar; 35(3):405-8. PubMed ID: 2537687
[TBL] [Abstract][Full Text] [Related]
22. [Experimental and clinical studies on a TPA kit, Prolifigen].
Ayabe Z; Ichiya Y; Yamaguchi I; Kuwabara Y; Wada M; Katsuragi M; Matsuura K
Radioisotopes; 1985 Apr; 34(4):230-3. PubMed ID: 4023281
[No Abstract] [Full Text] [Related]
23. [CA 19-9 enzyme immunoassay].
Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
[TBL] [Abstract][Full Text] [Related]
24. [Detection of pancreatic cancer by Eruza-CA19-9 kit].
Kanamori I; Nakano S; Yoshida H; Yabashi T; Higuchi C; Yanase M; Iwata F; Kawase A; Hattori Y; Yamada Y
Radioisotopes; 1985 Dec; 34(12):689-91. PubMed ID: 3867981
[No Abstract] [Full Text] [Related]
25. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
Nishida K
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of pancreatic oncofetal antigen, pancreatic cancer associated antigen assay as tumor markers].
Shimano T; Morimoto H; Saito M; Mori T
Nihon Rinsho; 1990 Feb; 48 Suppl():917-9. PubMed ID: 2192174
[No Abstract] [Full Text] [Related]
28. [Basic and clinical studies on SPan-1 RIABEAD kit: usefulness in patients with pancreatic and biliary tract cancer].
Watanabe Y; Endo K; Nakajima K; Hattori N; Sakahara H; Saga T; Nakai T; Hosono M; Yao ZS; Baba N
Kaku Igaku; 1989 Dec; 26(12):1559-65. PubMed ID: 2622087
[No Abstract] [Full Text] [Related]
29. [Clinical significance of Span-1 antigen assay as a tumor marker].
Satake K; Chung YS; Umeyama K
Nihon Rinsho; 1990 Feb; 48 Suppl():1053-6. PubMed ID: 2355504
[No Abstract] [Full Text] [Related]
30. [Fundamental and clinical evaluation of a tissue polypeptide antigen (TPA) kit--TPA as a tumor marker].
Masaka M; Yoshimi T
Radioisotopes; 1983 Dec; 32(12):633-6. PubMed ID: 6676781
[No Abstract] [Full Text] [Related]
31. [Fundamental and clinical evaluation of radioimmunoassay for tissue polypeptide antigen (TPA)].
Nishikawa A; Suehiro M; Ishimura J; Fukuchi M
Kaku Igaku; 1984 Jan; 21(1):91-100. PubMed ID: 6737796
[No Abstract] [Full Text] [Related]
32. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of serum CA 19-9 in malignant tumors.
Ding HJ; Wu CC; Yang CC; Her SS; Wu LL; Ker CG; Huang TJ
Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Jun; 3(6):400-6. PubMed ID: 2838648
[No Abstract] [Full Text] [Related]
34. Biochemical and immunologic diagnosis of cancer. Colorectal cancer.
von Kleist S
Tumour Biol; 1987; 8(2-3):78-83. PubMed ID: 3329404
[No Abstract] [Full Text] [Related]
35. [Studies on a solid phase CEA radioimmunoassay].
Nagata A
Kaku Igaku; 1983 Nov; 20(9):1377-86. PubMed ID: 6676524
[No Abstract] [Full Text] [Related]
36. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
[TBL] [Abstract][Full Text] [Related]
37. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG.
Mitchell H; Seckl MJ
Mol Cell Endocrinol; 2007 Jan; 260-262():310-3. PubMed ID: 17069967
[No Abstract] [Full Text] [Related]
38. [Clinical evaluation of serum levels of CA-125 in patients with digestive diseases].
Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Kawakami H; Okai T; Takahashi Y; Mai M; Hattori N
Nihon Shokakibyo Gakkai Zasshi; 1987 Oct; 84(10):2386-92. PubMed ID: 3481416
[No Abstract] [Full Text] [Related]
39. [Pancreatic oncofetal antigen (POA)].
Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002
[TBL] [Abstract][Full Text] [Related]
40. [Fundamental and clinical evaluation of CEA kit (CEA . RIABEAD)].
Kuwabara Y; Ichiya Y; Baba Y; Ayabe Z; Wada M; Katsuragi M; Matsuura K
Kaku Igaku; 1984 Nov; 21(11):1513-9. PubMed ID: 6530830
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
